Publications

The publication of research results is a fundamental requirement for improving treatment concepts across the board. iOMEDICO supports the international guidelines on transparency and publication of medical research results.

We regularly present our data at national and international conferences. Our publications appear in scientifically renowned, international journals. Authors are principal investigators, investigators with a high number of participating patients, and iOMEDICO scientists.

TITEL
STUDIE
JAHR
Bendamustine versus chlorambucil in treatment-naive patients with B-cell chronic lymphocytic leukemia (B-CLL): Results of an international phase III study.

Knauf, W.U., Lissichkov, T., Aldaoud, A., Herbrecht, R., Liberati, A.M., Loscertales, J., Juliusson, G., Dittrich, C., Merkle, K., 2007.

Blood 110(11), 2043.

Abstract

Indikation: Haemoblastoma, Hämoblastosen / Veranstaltung: ASH / Journal: Blood
02 CLL III
2007
Xeloda in Adjuvant Colon Cancer Therapy (X-ACT) trial: overview of efficacy, safety, and cost-effectiveness.

Twelves, C.J., 2006.

Clin Colorectal Cancer 6, 278–287.

Abstract

Indikation: Colorectal Cancer, Kolorektalkarzinom / Veranstaltung: - / Journal: Clinical Colorectal Cancer
X-ACT
2006
Capecitabine as adjuvant treatment for stage III colon cancer.

Twelves, C., Wong, A., Nowacki, M.P., Abt, M., Burris, H., Carrato, A., Cassidy, J., Cervantes, A., Fagerberg, J., Georgoulias, V., Husseini, F., Jodrell, D., Koralewski, P., Kröning, H., Maroun, J., Marschner, N., McKendrick, J., Pawlicki, M., Rosso, R., Schüller, J., Seitz, J.-F., Stabuc, B., Tujakowski, J., Van Hazel, G., Zaluski, J., Scheithauer, W., 2005.

N Engl J Med 352, 2696–704. doi:10.1056/NEJMoa043116

Abstract

Indikation: Colorectal Cancer, Kolorektalkarzinom / Veranstaltung: - / Journal: New England Journal of Medicine
X-ACT
2005
Prospective, double-blind, placebo-controlled, multicenter, randomized phase III study with orally administered budesonide for prevention of irinotecan (CPT-11)-induced diarrhea in patients with advanced colorectal cancer.

Karthaus, M., Ballo, H., Abenhardt, W., Steinmetz, T., Geer, T., Schimke, J., Braumann, D., Behrens, R., Behringer, D., Kindler, M., Messmann, H., Boeck, H.-P., Greinwald, R., Kleeberg, U., 2005.

Oncology 68, 326–32. doi:10.1159/000086971

Abstract

Indikation: Colorectal Cancer, Kolorektalkarzinom / Veranstaltung: - / Journal: Oncology
BUC-37/CID
2005
Oral capecitabine as an alternative to i.v. 5-fluorouracil-based adjuvant therapy for colon cancer: safety results of a randomized, phase III trial.

Scheithauer, W., McKendrick, J., Begbie, S., Borner, M., Burns, W.I., Burris, H.A., Cassidy, J., Jodrell, D., Koralewski, P., Levine, E.L., Marschner, N., Maroun, J., Garcia-Alfonso, P., Tujakowski, J., Van Hazel, G., Wong, A., Zaluski, J., Twelves, C., 2003.

Ann. Oncol. 14, 1735–1743.

Abstract

Indikation: Colorectal Cancer, Kolorektalkarzinom / Veranstaltung: - / Journal: Annals of Oncology
X-ACT
2003
Budesonide for prevention of irinotecan (CPT-11)-induced diarrhea. Results of a double-blind, placebo-controlled, multicenter, randomized phase-III-study in patients with advanced colorectal cancer (CRC).

Karthaus, M., Ballo, H., Steinmetz, T., Geer, T., Schimke, J., Braumann, D., Behrens, R., Kindler, M., Greinwald, R., Kleeberg, U., 2003.

Indikation: Colorectal Cancer, Kolorektalkarzinom / Veranstaltung: ASCO / Journal: -
BUC-37/CID
2003